Abstracts Archive - Page 211 of 2425 - ACR Meeting Abstracts

Abstract Number: 0694 • ACR Convergence 2023
Off-label Use of Biologics in Urticarial Vasculitis: A European Cohort Study
Lucas Maisonobe¹, Anne-Sophie Korganow², Alvise Berti³, Alban DEROUX⁴, Nicolas Dupin⁵, Selim Aractingi⁵, Giacomo Emmi⁶, Frédéric Vandergheynst⁷, Marc Fabre⁸, Nicolas Kluger⁹, Marielle Roux⁸, Noemie Abisror¹⁰, Audrey Benyamine¹¹, Giulia Cassone¹², Francois Chasset¹³, Marie-Sylvie Doutre¹⁴, Aurelie Foucher¹⁵, Caroline Freguin¹⁶, Delphine Gobert¹⁷, Yannick Gombeir⁷, José Hernandez-Rodriguez¹⁸, Noémie Legouellec¹⁹, Anne-Lise Pinault²⁰, Dimitri Titeca-Beauport²¹, Marie Jachiet²² and Benjamin Terrier²³, ¹Assistance Publique - Hopitaux de Paris, Paris, France, ²Strasbourg University Hospital, Strasbourg, France, ³University of Trento, Rochester, MN, ⁴CHU de Grenoble, Grenoble, France, ⁵CHU Cochin, Paris, France, ⁶University of Florence, Florence, Italy, ⁷Université Libre de Bruxelles, Bruxelles, Belgium, ⁸Centre Hospitalier Pierre Oudot, Bourgoin Jallieu, France, ⁹Helsinki University Central Hospital, Helsinki, Finland, ¹⁰Internal Medicine Saint Antoine Hospital, Paris, France, ¹¹Hopital Nord Marseille, Marseille, France, ¹²Universita degli Studi di Modena e Reggio, Modena, Italy, ¹³Dermatology Department, Tenon Hospital, Paris, France, ¹⁴CHU Bordeaux, Bordeaux, France, ¹⁵CHU de la Réunion, Saint pierre, France, ¹⁶Centre Hospitalier Saint-Brieuc, Saint Brieux, France, ¹⁷CHU Sant-Atoine, Paris, France, ¹⁸Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁹Centre Hospitalier de Valenciennes, Valenciennes, France, ²⁰Centre Hospitalier Epinal, Epinal, France, ²¹CHU Amiens, Amiens, France, ²²CHU Saint-Louis, Paris, France, ²³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Urticarial vasculitis (UV) is characterized by atypical urticarial lesions and leukocytoclastic vasculitis, sometimes with extra-cutaneous manifestations. First-line treatment is often based on colchicine, hydroxychloroquine,…
Abstract Number: 0695 • ACR Convergence 2023
Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Sabahat Usmani¹, Yanint Raksadawan¹, Amro Taha¹, Harigopal Sandhyavenu¹, Jalpan Patel¹, Thatiana Schulze Goni¹, Hafiz Muhammad Waqar Younas¹ and Irisha Badu², ¹Weiss Memorial Hospital, Chicago, IL, ²Onslow Memorial Hospital, Jacksonville, FL
Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…
Abstract Number: 0662 • ACR Convergence 2023
Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giovanna Cuomo⁴, Lidia P Ananieva⁵, Eric Hachulla⁶, Vanessa Smith⁷, Ana Maria Gheorghiu⁸, Radim Becvar⁹, Nicolas Hunzelmann¹⁰, Daniel Furst¹¹, Vera Ortiz-Santamaria¹², Patricia Carreira¹³, Francesco Del Galdo¹⁴, marco Matucci Cerinic¹⁵ and Anna Maria Hoffmann-Vold¹⁶, ¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ⁵V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, ⁶University of Lille, Lille, France, ⁷Ghent University Hospital, Gent, Belgium, ⁸Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, ⁹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ¹⁰University of Kšln, Kšln, Germany, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Granollers, Granollers, Spain, ¹³Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁴University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ¹⁵Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁶Oslo University Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: The treatment armamentarium with immunosuppressive treatments (ISTs) for interstitial lung disease (ILD) in systemic sclerosis (SSc) has greatly expanded. It is to date unclear…
Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Francois Maillet¹, Yann Nguyen², Olivier Espitia³, Laurent Perard⁴, Carlo Salvarani⁵, Etienne Rivière⁶, Cécile-Audrey Durel⁷, Philippe GUILPAIN⁸, Luc Mouthon⁹, Anna Kernder¹⁰, Javier Loricera¹¹, Pascal Cohen¹², Isabelle Melki¹³, Claire De Moreuil¹⁴, Nicolas Limal¹⁵, Arsène Mekinian¹⁶, Nathalie Costedoat-Chalumeau¹⁷, Nathalie Morel¹², Jonathan Boutemy¹⁸, Loic Raffray¹⁹, Jean-Sébastien Allain²⁰, Valerie Devauchelle²¹, Isabelle Kone-Paut²², Marc Fabre²³, Marie Durel²⁴, Antoine Dossier²⁵, Sébastien Abad²⁶, Marcella Visentini²⁷, Adrien Bigot²⁸, Halil Yildiz²⁹, Olivier Fain³⁰, Maxime Samson³¹, Guillaume Gondran³², Vered Abitbol¹ and Benjamin Terrier³³, ¹Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³CHU de Nantes, Nantes, France, ⁴CH Saint Hoseph Saint Luc, Lyon, France, ⁵Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁶CHU Bordeaux, Bordeaux, France, ⁷CHU Lyon, Lyon, France, ⁸University of Montpellier, Montpellier, France, ⁹Hopital Cochin - Paris University, Paris, France, ¹⁰HHU Düsseldorf, Düsseldorf, Germany, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²CHU Cochin, Paris, France, ¹³Hopital Robert Debré, Sérurier, France, ¹⁴CHU de Brest, Brest, France, ¹⁵AP-HP, Créteil, France, ¹⁶Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁷Inserm DR Paris 5, Paris, France, ¹⁸CHU de Caen, Caen, France, ¹⁹CHU la Réunion, La Réunion, France, ²⁰CHU Rennes, Rennes, France, ²¹UBO, Brest, France, ²²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ²³CH Bourgoin-Jallieu, Bourgoin-Jallieu, France, ²⁴CH Metz, Metz, France, ²⁵AP-HP, Paris, France, ²⁶Avicenne Hospital, Bobigny, France, ²⁷Rome Hospital, Rome, France, ²⁸Tours Hospital, Tours, France, ²⁹Saint Luc Hospital, Bruxelles, Belgium, ³⁰Hopital SAINT ANTOINE APHP, Paris, France, ³¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³²Limoges Hospital, Limoges, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…
Abstract Number: 0587 • ACR Convergence 2023
Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data
Daniel Moldaver¹, Seth Anderson², Marguerite Bracher³, Roger A. Levy⁴, Holly A. Quasny⁵, Robert Wood⁶, Rosie Wild⁶, Alexandra Cusmano⁶ and Elke Rottier⁶, ¹GlaxoSmithKline, Value Evidence and Outcomes, Ontario, Canada, ²GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ³GlaxoSmithKline, Value Evidence and Outcomes, Stevenage, United Kingdom, ⁴GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁵GlaxoSmithKline, Research & Development, Durham, NC, ⁶Adelphi Real World, Real-World Evidence, Cheshire, United Kingdom
Background/Purpose: The clinical effectiveness of 6-month IV BEL use in SLE has previously been described in a post hoc pooled analysis from six OBSErve cohort…
Abstract Number: 0637 • ACR Convergence 2023
Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort
Hilde Jenssen Bjørkekjær¹, Cosimo Bruni², Cathrine Brunborg³, Patricia Carreira⁴, Paolo Airò⁵, Carmen Pilar Simeon-Aznar⁶, Marie-Elise Truchetet⁷, Alessandro Giollo⁸, Alexandra Balbir-Gurman⁹, Mickael Martin¹⁰, Christopher Denton¹¹, Armando Gabrielli¹², Havard Fretheim¹³, Imon Barua¹³, Helle Bitter¹⁴, Oyvind Midtvedt¹³, Torhild Garen¹⁵, Kaspar Broch¹⁶, Arne Andreassen¹⁷, Yoshiya Tanaka¹⁸, Gabriela Riemekasten¹⁹, Ulf Müller-Ladner²⁰, marco Matucci Cerinic²¹, Ivan Castellvi²², Elise Siegert²³, Eric Hachulla²⁴, Oliver Distler² and Anna-Maria Hoffmann-Vold¹³, ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁶Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy, Verona, Italy, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ¹¹University College London, London, United Kingdom, ¹²Ospedali Riuniti Marche, Ancona, Italy, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Sorlandet sykehus, Kristiansand, Norway, ¹⁵Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ¹⁶Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, KG Jebsen center, Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, ¹⁷Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, ¹⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ²⁰Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²²Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ²³Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ²⁴University of Lille, Lille, France
Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…
Abstract Number: 0584 • ACR Convergence 2023
Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator
Thomas Hoyler¹, Daniel Strasser¹, Ouali Berkani², Peter Cornelisse¹, Mark Murphy¹ and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ²IDORSIA, Allschwil, Switzerland
Background/Purpose: In SLE, aberrant lymphocyte activation and autoantibody production result in deposition of immune complexes and contribute to tissue damage. Cenerimod, a highly selective S1P1…
Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Sabahat Usmani¹, Catherine Lavallee², Maria Antonelli³ and Cuoghi Edens⁴, ¹Weiss Memorial Hospital, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, ³MetroHealth System, Cleveland, OH, ⁴University of Chicago, Chicago, IL
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…
Abstract Number: 0644 • ACR Convergence 2023
Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Carina Mihai⁶, Oyvind Midtvedt¹, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
Abstract Number: 0661 • ACR Convergence 2023
Assessment of Systemic Sclerosis-Associated Myocarditis: A Single Center Case Series Study
Nafsika Gerolymatou¹, NIck Koletsos¹, Aliki Venetsanopoulou², Anastasia Giantsouli³, Sophie Mavrogeni⁴ and PARASKEVI VOULGARI⁵, ¹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²Medical School of Ioannina, Ioannina, Greece, ³Radiology Department, University Hospital of Ioannina, Ioannina, Greece, ⁴Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece, ⁵Rheumatology Clinic, Department of Internal Medicine, University of Ioannina, Ioannina, Greece
Background/Purpose: Myocardial involvement is a significant contributor to mortality in patients with Systemic Sclerosis (SSc). The objective of this study was to analyze the clinical…
Abstract Number: 0691 • ACR Convergence 2023
Recognizing the New Disorder “Idiopathic Hypocryoglobulinaemia” in Patients with Previously Unidentified Clinical Conditions
Dario Roccatello¹, Savino Sciascia², carla naretto³, ANTONELLA BARRECA⁴, MASSIMO RADIN⁵, IRENE CECCHI⁵, ALICE BARINOTTI⁵, ELENA RUBINI⁵, SILVIA GRAZIETTA FODDAI⁵, laura solfietti³, laura battaglia³, lucia vizziello³, ROBERTA FENOGLIO³ and DANIELA ROSSI³, ¹University of Torino, Torino, Italy, ²University of Turin, Torino, Italy, ³University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, ⁴Pathology Unit, Città della Salute e della Scienza, Turin, Italy, ⁵University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
Background/Purpose: A considerable number of patients with high clinical suspicion for cryoglobulinaemic vasculitis either show negative results for the detection of cryoglobulins or show only…
Abstract Number: 0485 • ACR Convergence 2023
Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial
Lihi Eder¹, Alexis R Ogdie², Subhashis Banerjee³, Miroslawa Nowak³, Thomas Lehman⁴ and Philip J. Mease⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²University of Pennsylvania, Philadelphia, PA, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Sex differences have been reported in pathophysiology, clinical manifestations, and treatment responses in several rheumatic diseases, including psoriatic arthritis (PsA).1 Although PsA is equally…
Abstract Number: 0693 • ACR Convergence 2023
Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus
Ana Belen Arevalo¹, Harshvardhan Zala², Andrea Ramirez Gomez¹ and Kichul Ko³, ¹University of Chicago, Chicago, IL, ²Indiana University School of Medicine, Indianapolis, IN, ³The University of Chicago, Chicago, IL
Background/Purpose: Cardiovascular disease (CVD) has been reported as the most common cause of death in ANCA-associated vasculitis (AAV)1,2. Systemic inflammation, in addition to traditional risk…
Abstract Number: 0595 • ACR Convergence 2023
Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Gelareh Atefi⁶, Gary Bryant⁶, Micki Hultquist⁷, Raj Tummala⁷, Gabriel Abreu⁸, Catharina Lindholm⁸ and Hussein Al-Mossawi⁹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In patients with SLE, nephritis is present in 50%–60% during the first 10 years of disease.1 Renal involvement is associated with poor clinical outcomes…
Abstract Number: 0600 • ACR Convergence 2023
Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline
Prathyusha Bachali¹, Amrie Grammer² and Peter Lipsky², ¹AMPEL BioSolutions, Redmond, WA, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Baricitinib is an inhibitor of Jak1 approved for treatment of rheumatoid arthritis, atopic dermatitis, alopecia areata and Covid-19. A phase 2 trial showed success…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].